Corporate Presentation

Rare diseases SBS Glepaglutide Phase 3 clinical program focused on potential regulatory approval in 2024 ZBAL& ZEALAND PHARMA Phase 3a pivotal trial Phase 3 extension trials Phase 3b nutritional status EASE 1 NCT03690206 Placebo, once and twice weekly treatment (~24 weeks) EASE 2 Once and twice weekly long-term treatment (~104 weeks) NCT03905707 EASE 3 NCT04881825 Once weekly long-term treatment w/ autoinjector (~104 weeks) EASE 4 Absorption of fluids & energy (~24 weeks) NCT04991311 1 https://clinicaltrials.gov/ct2/show/NCT03690206; 2 https://clinicaltrials.gov/ct2/show/NCT03905707; 3 https://clinicaltrials.gov/ct2/show/NCT04881825; 4 https://clinicaltrials.gov/ct2/show/NCT04991311 41

View entire presentation